Trial No.: TRIO-US L-07
A Phase 2 Study of Continuous Talazoparib Plus Intermittent Low-Dose Temozolomide in Patients with Relapsed or Refractory Extensive Stage Small Cell Lung Cancer.
Trial No.: BMS CA209-816
Randomized, Open-Label, Phase Three, Trial of Nivolumab plus Ipilimumab plus Platinum Doublet Chemotherapy vs. Platinum Doublet Chemotherapy in Early Stage NSCLC.
Trial No.: Novartis CACZ885T2301
A phase III, double blind, placebo-controlled study evaluating the efficacy and safety of canakinumab versus placebo as adjuvant therapy in adult subjects with stages AJCC/UICC v. 8 II-IIIA and IIIB (T>5cm N2) completely resected (R0) non-small cell lung cancer (NSCLC).
Trial No.: Astra Zeneca AZ933QC0001 ADRIATIC
A Phase III randomized, double blind, placebo-controlled study of Durvalumab or Durvalumab and Tremelimumab as consolidation treatment for Stage I-III Limited Disease Small Cell Lung Cancer (SCLC) patients who have not progressed following concurrent chemoradiation therapy.
©2019 Fort Wayne Medical Oncology and Hematology. All Rights Reserved.